Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.

ABSTRACT

During a phase 3 study evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64983-985).